# Lentivirally Redirected CD123 Autologous T Cells in AML

> **NCT03766126** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 22 (actual)

## Conditions studied

- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia, Adult
- Acute Myeloid Leukemia, Refractory

## Interventions

- **BIOLOGICAL:** CART123 cells; cyclophosphamide; fludarabine

## Key facts

- **NCT ID:** NCT03766126
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-06
- **Primary completion:** 2033-12-03
- **Final completion:** 2033-12-03
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03766126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03766126, "Lentivirally Redirected CD123 Autologous T Cells in AML". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03766126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*